News | Heart Valve Technology | November 20, 2023

Late-breaking Data Show an Aspirin-free Medication Regimen Benefits People with Abbott’s HeartMate 3 Heart Pump

New data from the ARIES trial show for the first time that an aspirin-free regimen can improve outcomes for people living with the heart pump by reducing hospitalizations without increasing the risk of blood clots 

New data from the ARIES trial show for the first time that an aspirin-free regimen can improve outcomes for people living with the heart pump by reducing hospitalizations without increasing the risk of blood clots

November 20, 2023 — Abbott announced new late-breaking data that show advanced heart failure patients living with its HeartMate 3 heart pump who didn't receive aspirin as part of their blood-thinning medication regimen experienced fewer complications from bleeding and were associated with reduced hospital visits compared to patients who took aspirin daily following their implant. The data from the ARIES trial is the first to potentially shift how physicians manage their patients living with a HeartMate 3 heart pump. ARIES marks the first international, placebo-controlled, randomized clinical study to assess whether the absence of aspirin is safe and decreases bleeding in people with the HeartMate 3 left ventricular assist device (LVAD, or heart pump).   

The data were presented during a late-breaking presentation at the 2023 American Heart Association's Scientific Sessions in Philadelphia and simultaneously published in The Journal of the American Medical Association

Heart Pump Patients See Benefit in Aspirin-Free Regimen 

The ARIES trial studied more than 600 patients and found that HeartMate 3 patients who didn't receive aspirin but continued using the standard post-implant vitamin-K antagonist (VKA) treatment regimen met the primary endpoint by showing non-inferiority of no aspirin to aspirin. The HeartMate 3 patients who did not take aspirin spent 47% fewer days in the hospital due to a nearly 40% decrease in bleeding events compared to patients who continued to take aspirin daily. 

While the HeartMate 3 is associated with lower rates of complications compared to previous generation heart pumps, bleeding remains a leading cause for rehospitalizations. The ARIES trial demonstrated a reduction in bleeding events in patients without aspirin, which could lead to an important change in management of patients with a HeartMate 3. 

"The ARIES study moves the needle forward in improving the journey of advanced heart failure patients with a marked improvement in bleeding events, healthcare resource use and cost-savings by a simple decision to avoid the use of aspirin," said Mandeep R. Mehra, M.D., executive director of the Center for Advanced Heart Disease and the William Harvey Distinguished Chair at Brigham and Women's Hospital in Boston, Mass. "The data is so compelling that the magnitude of benefit observed in avoiding aspirin is similar to the impact of introducing a new device to the market." 

Aspirin-Free Regimen Reduces Costs for HeartMate 3 Patients


In addition to finding reductions in bleeding and hospital visits for bleeding complications, the ARIES trial also revealed cost-savings for heart failure patients who did not take aspirin following implant of an Abbott HeartMate 3 pump. One year after receiving the device, there was a 41% reduction in estimated costs related to bleeding events. The data also found this same group had no elevated risk in developing thrombosis (a blood clot that increases the risk of stroke). 

"There is a general consensus within the medical community that aspirin use should be a mandatory part of the treatment regimen for heart failure patients living with an LVAD; however, those assumptions were largely driven by observational data that have rarely been challenged," said Robert Kormos, M.D., divisional vice president, global medical affairs, Abbott's heart failure business. "The ARIES trial estimates that for every 100 people with the HeartMate 3, not taking aspirin prevents nearly 15 major bleeding events within their first year with the device. That equates to many more moments these patients can spend with their loved ones living a fuller life." 

About the ARIES Trial  

The ARIES trial was an international, randomized study of either aspirin (100mg/day) or placebo with VKA therapy in advanced heart failure patients with Abbott's HeartMate 3 LVAD. The study (July 2020 – September 2022) was conducted across 51 centers and included over 600 patients in the United States, Canada, the United Kingdom, France, Italy, Austria, Czech Republic, Kazakhstan and Australia. ARIES met its primary endpoint which found that for patients with the HeartMate 3, an aspirin-free medication regimen is non-inferior to an anti-thrombotic regimen that includes aspirin. The trial is part of Abbott's continued commitment to investments in heart failure and clinical science innovation to further improve the lives of people with advanced heart failure.   

"Abbott has focused its investments on ways that we can continue to improve the outcomes for the thousands of patients a year who are eligible to receive a heart pump," said Keith Boettiger, vice president, Abbott's heart failure business. "With the ARIES trial, we've identified an important new approach to patient management that doctors can consider to reduce bleeding risk for their patients and make LVAD therapy more accessible to patients who need this life-saving device." 

Indications and Important Safety Information:

The HeartMate 3 Left Ventricular Assist System (LVAS) is indicated for providing short- and long-term mechanical circulatory support (e.g., as bridge to transplant or myocardial recovery, or destination therapy) in adult and pediatric patients with advanced refractory left ventricular heart failure and with an appropriate body surface area. It is contraindicated for patients who cannot tolerate, or who are allergic to, anticoagulation therapy. 

For additional U.S. important safety information for the Abbott HeartMate 3, visit: HeartMate 3 LVAD Indications, Safety and Warnings | Abbott (cardiovascular.abbott)

The ARIES HeartMate 3 clinical study evaluated a new clinical approach to patient management, which has not been reviewed by the U.S. Food and Drug Administration (FDA). 

Labeling changes related to the study's anticoagulation regimen have not been approved by the FDA at this time. 

For more information: www.abbott.com 

 

Related content:  

Effectively Treating Heart Failure: New Technology on the Horizon  

Abbott Announces Future of Biowearables at Consumer Electronics Show  

First Woman in World Receives New Type of Artificial Heart   

FDA Clears HeartMate 3 for Heart Failure Patients Not Eligible for Transplant  

  

Related Content on the HeartMate III:  

Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System  

VIDEO: Therapies for Advanced Heart Failure — interview with David Lanfear M.D., FACC, head of advanced heart failure and cardiac transplantation, Henry Ford Hospital, Detroit  

Leading Cardiovascular Societies Release New Guidance on Use of Heart Pumps 


Related Content

News | Heart Valve Technology

April 17, 2024 —CPR Therapeutics, Inc. (CPR-T), an early-stage medtech startup funded by the N.I.H and N.S.F to develop ...

Home April 17, 2024
Home
News | Heart Valve Technology

April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health ...

Home April 01, 2024
Home
News | Heart Valve Technology

January 4, 2024 — Findings from a published case series research letter by the Henry Ford Health Structural Heart ...

Home January 04, 2024
Home
News | Heart Valve Technology

December 22, 2023 — TRiCares SAS (“TRiCares”), a privately held pioneer in the field of minimally invasive treatment of ...

Home December 22, 2023
Home
News | Heart Valve Technology

December 18, 2023 — Death rates related to infective endocarditis declined in most adults across the U.S. within the ...

Home December 18, 2023
Home
News | Heart Valve Technology

December 12, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement ...

Home December 12, 2023
Home
News | Heart Valve Technology

October 24, 2023 — Abiomed, part of Johnson & Johnson MedTech[1], announced that novel data from seven research studies ...

Home October 24, 2023
Home
News | Heart Valve Technology

October 17, 2023 — The Patel Children's Heart Institute at St. Joseph's Children's Hospital achieved a milestone ...

Home October 17, 2023
Home
News | Heart Valve Technology

August 2, 2023 — Foldax, Inc., a leader in the development of innovative, polymer heart valves, today announced that the ...

Home August 02, 2023
Home
Subscribe Now